In patients with neurological diseases like Alzheimer’s disease and multiple sclerosis, immune cells in the brain known as microglia that normally fulfill beneficial functions become harmful to neurons, leading to cognitive dysfunction and motor impairment. These harmful immune cells may also contribute to age-related cognitive decline in people without dementia.
For some time, scientists have been trying to better understand the triggers responsible for turning good microglia bad, and their exact contribution during disease. If they could identify what makes microglia toxic, they could find new ways to treat neurological diseases.
Now, researchers at Gladstone Institutes led by Senior Investigator Katerina Akassoglou, PhD, showed that exposure to blood leaking into the brain turns on harmful genes in microglia, transforming them into toxic cells that can destroy neurons.
The scientists discovered that a blood protein called fibrin—which normally aids blood clotting—is responsible for turning on the detrimental genes in microglia, both in Alzheimer’s disease and multiple sclerosis. The findings, published in the journal Nature Immunology, suggest that counteracting the blood toxicity caused by fibrin can protect the brain from harmful inflammation and loss of neurons in neurological diseases.
“Our study answers, for the first time in a comprehensive way, how blood that leaks into the brain hijacks the brain’s immune system to cause toxic effects in brain diseases,” says Akassoglou, who is also director of the Center for Neurovascular Brain Immunology at Gladstone and a professor of neurology at UC San Francisco (UCSF). “Knowing how blood affects the brain could help us develop innovative treatments for neurological diseases.”
Individuals with neurological diseases like Alzheimer’s disease and multiple sclerosis have abnormalities within the vast network of blood vessels in their brain, which allow blood proteins to seep into brain areas responsible for cognitive and motor functions. Blood leaks in the brain occur early and correlate with worse prognosis in many of these diseases.
To understand which proteins in the blood affect gene and protein changes in immune cells, Akassoglou and her team took a systematic approach to determine how losing key blood proteins—such as albumin, complement, and fibrin—would affect immune cells in mice.
They analyzed the effect of the blood proteins with a suite of advanced molecular and computational technologies in collaboration with Nevan Krogan, PhD, senior investigator at Gladstone and director of the Quantitative Biosciences Institute at UCSF, and Alex Pico, PhD, research investigator and director of the Bioinformatics Core at Gladstone.
In the new study, the researchers found that different blood proteins activate distinct molecular processes in microglia. What’s more, they identified that fibrin is responsible for driving unique gene and protein activities that make microglia toxic to neurons. The other blood proteins tested were not mainly responsible for these toxic effects.
“We combined cutting-edge tools to capture a broad view of all the microglia processes triggered by distinct blood proteins,” says Andrew Mendiola, PhD, a scientist in Akassoglou’s lab and first author of the study. “Fibrin stood out, as it triggered a dramatic gene response in microglia, which mirrored gene signatures identified in chronic neurological diseases such as Alzheimer’s disease.”
In prior research, Akassoglou and her team had discovered that fibrin can activate microglia and promote cognitive impairment in mice. Indeed, the researchers were able to narrow down fibrin’s bad influence to a specific inflammatory region of the protein. This region does not impact fibrin’s critical role in blood clotting. In the new study, the team showed that removing that inflammatory region reduced fibrin’s ability to turn on toxic genes in microglia, and restored the protective functions of these immune cells.
To assess whether their findings are relevant to disease, the researchers used a technique they developed to identify toxic gene activities in cells in mouse models of Alzheimer’s disease and of multiple sclerosis. In both types of models, fibrin activated microglia genes involved in neurodegeneration and oxidative stress, processes that have been linked to both Alzheimer’s disease and multiple sclerosis.
“We think that, across neurological diseases, fibrin deposits at sites of blood leaks might drive toxic immune responses,” Mendiola says. “Identifying approaches to selectively inhibit these toxic responses could be a game changer for treating disease.”
“By targeting fibrin, we can block toxic microglia cells without affecting their protective functions in the brain.”
Akassoglou’s lab has already developed one such drug, a therapeutic monoclonal antibody against fibrin’s inflammatory domain. The antibody blocks the detrimental effects of fibrin without adverse effects on blood clotting, and protects from multiple sclerosis and Alzheimer’s disease in mice. A humanized version of this first-in-class fibrin immunotherapy has now started Phase 1 safety clinical trials.
“Neutralizing blood toxicity could protect the brain from harmful inflammation and restore neuronal connections required for cognitive functions,” says Akassoglou. “By targeting fibrin, we can block toxic microglia cells without affecting their protective functions in the brain.”
The study generated a large amount of molecular data that is now freely available for other researchers to use. The open-access atlas of how the blood affects the brain could be further analyzed to reveal other functions of blood proteins and support the discovery of new drugs and biomarkers.
“These exciting findings change the way we think about blood proteins, from secondary bystanders to primary drivers of harm in the brain,” says Lennart Mucke, MD, director of the Gladstone Institute of Neurological Disease. “The mechanisms identified in this study could be at work in a range of neurological conditions involving blood leaks in the brain, including neurodegenerative disorders, autoimmune diseases, stroke, and traumatic brain injury. Therefore, they have far-reaching therapeutic implications.”
Direct line: 415.734.5000
The paper “Defining blood-induced microglia functions in neurodegeneration through multiomic profiling” was published in the journal Nature Immunology on June 8, 2023.
Other authors are Zhaoqi Yan, Karuna Dixit, Jeffrey Johnson, Anke Meyer-Franke, Min-Gyoung Shin, Yu Yong, Ayushi Agrawal, Eilidh MacDonald, Gayathri Muthukumar, Clairice Pearce, Nikhita Arun, Belinda Cabriga, Rosa Meza-Acevedo, Maria del Pilar S. Alzamora, and Jae Kyu Ryu of Gladstone; and Mehdi Bouhaddou and Scott Zamvil of UCSF.
The work was supported by the National Institutes of Health (C06 RR018928, T32 AI007334, K99 NS126707, RF1 AG064926, R35 NS097976), the National Multiple Sclerosis Society (FG-1708-28925), the Berkelhammer Award for Excellence in Neuroscience, the BrightFocus Foundation (A2021019F), the Conrad N. Hilton Foundation (17348), the Ray and Dagmar Dolby Family Fund, Edward and Pearl Fein, and the Simon Family Trust.
Gladstone Institutes is an independent, nonprofit life science research organization that uses visionary science and technology to overcome disease. Established in 1979, it is located in the epicenter of biomedical and technological innovation, in the Mission Bay neighborhood of San Francisco. Gladstone has created a research model that disrupts how science is done, funds big ideas, and attracts the brightest minds.
At San Francisco’s Exploratorium, visitors sync their heartbeat with living heart cells; the first-of-its-kind exhibit was created through the museum’s long-running partnership with scientists at Gladstone Institutes.News Release Stem Cells/iPSCs Conklin Lab Yamanaka Lab Cardiovascular Disease Research (Publication)
In a new study that appears in Nature, researchers leveraged the power of a naturally occurring mutation in cancerous T cells to create a more powerful immunotherapyNews Release Research (Publication) Cancer Genomic Immunology Parker Institute for Cancer Immunotherapy Roybal Lab
New research from Gladstone may help in the development of new therapies that target the problem of cellular energy failure—a hallmark of Parkinson’s, Alzheimer’s, and aging in generalNews Release Research (Publication) Alzheimer’s Disease Parkinson’s Disease Neurological Disease Nakamura Lab CRISPR/Gene Editing